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Memantine Improves Attentional 
Processes in Fragile X-Associated 
Tremor/Ataxia Syndrome: 
Electrophysiological Evidence from 
a Randomized Controlled Trial
Jin-Chen Yang1,2, Annette Rodriguez1,3,*, Ashley Royston1,4,*, Yu-Qiong Niu1,2, Merve Avar1,5, 
Ryan Brill1,2, Christa Simon1,2, Jim Grigsby6, Randi J. Hagerman7,8 & John M. Olichney1,2
Progressive cognitive deficits are common in patients with fragile X-associated tremor/ataxia syndrome 
(FXTAS), with no targeted treatment yet established. In this substudy of the first randomized 
controlled trial for FXTAS, we examined the effects of NMDA antagonist memantine on attention and 
working memory. Data were analyzed for patients (24 in each arm) who completed both the primary 
memantine trial and two EEG recordings (at baseline and follow-up) using an auditory “oddball” task. 
Results demonstrated significantly improved attention/working memory performance after one 
year only for the memantine group. The event-related potential P2 amplitude elicited by non-targets 
was significantly enhanced in the treated group, indicating memantine-associated improvement 
in attentional processes at the stimulus identification/discrimination level. P2 amplitude increase 
was positively correlated with improvement on the behavioral measure of attention/working 
memory during target detection. Analysis also revealed that memantine treatment normalized the 
P2 habituation effect at the follow-up visit. These findings indicate that memantine may benefit 
attentional processes that represent fundamental components of executive function/dysfunction, 
thought to comprise the core cognitive deficit in FXTAS. The results provide evidence of target 
engagement of memantine, as well as therapeutically relevant information that could further the 
development of specific cognitive or disease-modifying therapies for FXTAS.
Prevalence of the fragile X gene (FMR1) premutation is ~1:150 in females and ~1:450 in males of the general 
population1. A portion of older FMR1 premutation carriers (~40% of males, ~16% of females) develop fragile 
X-associated tremor/ataxia syndrome (FXTAS), with intention tremor, cerebellar ataxia, polyneuropathy, and 
cognitive deficits—particularly executive dysfunction—as the primary symptoms2. Currently, medical interven-
tion for FXTAS is limited to symptom management2,3 (Hagerman et al. 2013).
Pronounced cognitive deficits in executive functioning, processing speed, and working memory are common 
in FXTAS4,5. Attention deficits modulated by FMR1 premutation are frequently self-reported by premutation 
carriers6. Moreover, the premutation has been associated with Autism and ADHD7,8. Inhibition and working 
memory are also impaired in carriers asymptomatic of FXTAS9,10. Radiological and neuropathological studies in 
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FXTAS revealed abnormalities in prefrontal and fronto-parietal regions crucial for top-down attentional control 
and working memory11–13.
Cellular neuropathological studies have demonstrated abnormal neuronal response to glutamate in the FMR1 
premutation14,15. In human induced pluripotent stem cell (iPSC)-derived neurons carrying the premutation, Liu 
and colleagues documented an increased response to glutamate, and higher amplitude and more frequent calcium 
spiking activity16.
Memantine, an uncompetitive NMDA glutamate receptor antagonist approved for the treatment of moderate 
to severe Alzheimer’s disease17, has thus been tested in the first randomized, double-blind, placebo-controlled 
clinical trial conducted in FXTAS. The main analyses showed no significant treatment effects on the primary 
outcome measures of intention tremor and executive dysfunction18. However, in a substudy utilizing cognitive 
event-related potentials (ERPs), memantine-associated benefits on both cued-recall memory and N400 repetition 
effect (an electrophysiological marker of semantic priming and verbal memory processes) were demonstrated19, 
indicating that ERPs offered a more sensitive measure of changes in cognitive processes compared to standard 
behavioral and neuropsychological tests. This notion is consistent with the suggestions that ERPs can provide 
a non-invasive and reliable approach to studying the effects of pharmacological interventions on neural pro-
cesses20,21. In the present study, effects of memantine treatment on attentional processes that are fundamental to 
executive function/dysfunction, the cardinal cognitive deficit in FXTAS, were investigated using ERPs obtained 
from an auditory “oddball” task, an extensively-studied paradigm engaging attentional processes22,23. In the audi-
tory oddball paradigm utilized in the current experiment, patients were instructed to detect the infrequent “odd-
ball” tone embedded in a train of non-target standard tones. Subjects were instructed to press a button to each 
target detected and also keep a mental count of the number of targets in that experimental block.
Our prior studies in premutation carriers using the same “oddball” paradigm have demonstrated an altered 
frontal P300 (P3) ERP component in FXTAS patients9,24, which tracks their executive dysfunction. The earlier 
abnormalities of prolonged N100 latency and reduced P200 (P2) amplitude were also found in a predominately 
male FXTAS group24 but not in female premutation carriers asymptomatic of FXTAS9. Based on both the NMDA 
modulation effects on auditory ERPs in animals25–28 and humans29–32, and our prior findings in FXTAS9,24, we 
hypothesized that 1-year of memantine treatment would improve attentional abilities as indexed by P2 and P3 
measures in the present study.
Results
Table 1 summarizes the group characteristics at baseline for 24 patients from each group (i.e., memantine and 
placebo) analyzed in the present study.
Behavioral performance. The response time (RT) and accuracy data for target detection at two visits and 
the change over one year (1-year minus baseline) are summarized in Table 2, with no statistically significant 
differences found for the RT or target detection accuracy between two groups (p’s ≥ 0.26). ANOVA of d′ , the 
sensitivity for target detection calculated using signal detection theory (d′ = normalized hit rate minus false 
alarm rate33), showed an insignificant trend of treatment × visit interaction (p = 0.13), with an increase in the 
Memantine 
(N = 24) Placebo (N = 24) p
Age 63.5 ± 9.7 65.1 ± 8.6 0.53
Education 15.7 ± 2.5 15.6 ± 3.1 0.86
MMSE 28.0 ± 3.5 28.5 ± 1.6 0.53
CGG repeats 88.1 ± 16.5 83.3 ± 18.1 0.39
Duration in trial 
(days) 361.8 ± 99.5 350.7 ± 64.3 0.65
FXTAS Stage 3.0 ± 0.9 3.1 ± 0.8 0.75
Table 1.  Group characteristics at Baseline: Mean ± SD. Abbreviation: MMSE = Mini-Mental State 
Examination. FXTAS = fragile X-associated tremor/ataxia syndrome.
Memantine Placebo
Baseline 1-year Δ Baseline 1-year Δ
RT (ms) 503 ± 90 505 ± 82 2.1 ms 500 ± 79 524 ± 91 24 ms
Accuracy % 95.2 ± 11.7 96.6 ± 7.5 1.4% 96.3 ± 4.7 94.8 ± 9.8 − 1.5%
|Count-Hit| 2.52 ± 2.95 1.27 ± 1.79 − 1.24 1.43 ± 1.14 2.07 ± 2.39 0.65
d' 6.02 ± 1.86 6.72 ± 2.35 0.70 5.79 ± 2.03 5.64 ± 1.97 − 0.15
Table 2.  Behavioral performance during auditory “oddball” task: Mean ± SD. Abbreviations: 1-year = 1-
year follow-up; RT = response time; Δ = 1-year − baseline; d′ = d-prime, the sensitivity measure in signal 
detection theory, calculated by subtracting the normalized values of the false alarm rates from that of the hit 
rates.
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memantine group, but a slight decrease in the placebo group. The marginially enhanced sensitivity for target 
detection as reflected by the d′ suggests a beneficial effect from the memantine treatment.
There was no group difference on the |count-hit| discrepancies (a behavioral attention/working memory 
measure obtained from the dual-response oddball task, contrasting the total correct button-presses and the 
reported mental count of targets) at either the baseline or follow-up visit (p = 0.79), however, ANOVA revealed 
a significant visit × treatment interaction (F1,46 = 8.64, p = 0.005, effect size η2 = 0.16). Follow-up within-group 
paired-samples t-tests showed that the |count-hit| discrepancy significantly decreased after 1-year treatment for 
the memantine group (t23 = 3.0, p = 0.006), but not for the placebo group which showed an insignificant increase 
of the |count-hit| discrepancy (t23 = − 1.32, p = 0.20). This result reflects improved attention and/or working 
memory after treatment with memantine.
ERP Results. Figures 1 and 2 depict the grand average ERPs to standard tones at the vertex (Cz) and the ERPs 
to target tones at 3 midline electrodes (i.e., Fz, Cz and Pz), respectively. In repeated-measures ANOVAs of the 
P2 data, a significant visit × treatment interaction was found for P2 amplitude (F1,44 = 4.26, p = 0.045, η2 = 0.88). 
Post-hoc analyses found significantly larger increases of the composite P2 amplitudes (averaged from the 
fronto-central cluster of 4 electrodes Fz, Cz, and FC1/2) in the memantine group compared to the placebo group 
Figure 1. ERPs to standard tones. (A) ERPs to standards at the vertex (Cz). (B) Topographic maps of P2 
amplitude to standard tones, 160–260 ms post-stimulus.
Figure 2. ERPs to targets. ERPs to targets at 3 midline electrodes (left panel), and topographic maps to targets 
across the N2 (upper) and P3 (lower) time windows (right panel).
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(1-year – baseline: memantine group = 0.79 ± 1.3 μV, placebo group = − 0.01 ± 1.2 μV; t46 = 2.19, p = 0.03). 
Post-hoc within-group paired-samples t-tests showed that the P2 amplitude was significantly enhanced after 
1-year intervention for the memantine group (t23 = − 2.88, p = 0.008), but not for the placebo group (t23 = 0.05, 
p = 0.96). No significant treatment effects were found for other ERP measures analyzed.
The ANOVA of P2 habituation effect (i.e., smaller response to later stimuli) found a significant treat-
ment × visit × trial position interaction (F1, 46 = 4.17, p = 0.049). Paired-samples t-tests revealed larger P2 ampli-
tude in response to the first 30 standard tones at the 1-year follow-up than at the baseline in the treated group 
(Fig. 3, mean increase across 4 electrodes: 1-year − baseline = 1.53 μV, t23 = − 3.56, p = 0.002), but not in the pla-
cebo group (mean decrease: 1-year − baseline = − 0.02 μV, t23 = − 0.63, p = 0.54). Furthermore, FXTAS patients 
who received the memantine treatment exhibited a normalized trend of habituation at the 1-year follow-up 
(1st 30 tones − last 30 tones = 0.82 μV) comparable to that in a group of 16 age-matched normal controls 
(0.51 μV). In contrast, FXTAS patients without an active memantine treatment (i.e., the placebo group as well as 
the treated group at baseline prior to the start of memantine) showed an insignificant trend of a reduced P2 ampli-
tude as well as a smaller and inversed P2 habituation effect compared to normal controls: P2 raw amplitude (aver-
aged across the 4 electrodes) in FXTAS = 0.89 μV, controls = 1.65 μV (t = 1.69, p = 0.095); P2 habituation effect in 
FXTAS = − 0.82 μV, NC = 0.51 μV; t = 1.78, p = 0.08), indicating that the increased P2 amplitude and habituation 
effect in FXTAS after memantine treatment reflect beneficial changes towards normalized brain responses.
Correlation Results. Correlations between CGG repeat length and the P2 measures were tested using linear 
regression. Across all patients, CGG repeat length was inversely associated with the composite P2 peak amplitude 
at the baseline visit (B = − 0.046, r = − 0.39, p = 0.014), suggesting a link between the FMR1 premutation and P2.
Across all participants, a significant correlation (B = − 0.178, r = − 0.32, p = 0.025) was observed between the 
1-year increase in the composite P2 amplitude (1-year − baseline) and the improvement (decrease from baseline 
to 1-year) on the behavioral measure of attention/working memory during the oddball task (i.e., the |count-hit| 
discrepancy). A similar trend of correlation was found within the memantine group (B = − 0.231, r = − 0.35, 
p = 0.09), but not in the placebo group (B = − 0.60, r = − 0.12, p = 0.56).
Discussion
No targeted treatment has yet been proven effective for FXTAS, a progressive adult-onset neurodegenerative dis-
order affecting many older FMR1 premutation carriers. The first report made based upon the larger cohort from 
which the current study was drawn18 concluded that memantine, an NMDA glutamate uncompetitive antagonist, 
showed no significant effects in FXTAS on the primary clinical and neuropsychological outcome measures of 
intention tremor severity and executive function. However, herein we have reported that patients with FXTAS 
administered memantine for one year showed enhanced neural correlates of attentional processes at the stimu-
lus identification/discrimination stage (i.e., the P2 ERP component obtained from an auditory oddball exper-
iment). Increases in P2 amplitude correlated with improved behavioral performance on an attention/working 
memory measure obtained from the oddball task (i.e., the |count-hit| discrepancy). These improvements were 
not observed among the placebo group, which exhibited a slight decrement in attention/working memory perfor-
mance after one year. Thus, we interpret these results as showing that memantine achieved “target engagement”, 
and the P2 can provide a “surrogate marker”21,34 for treatment response with improvements in cognitive domains 
of attention and working memory. However, one should also note that the cognitive effects of memantine were 
modest, highly significant for count-hit discrepancy, with insignificant trends towards improvement on response 
time (RT) and target detection accuracy. Additionally, across all patients, the P2 amplitude at baseline was nega-
tively correlated with CGG repeat length. Although we also expected a treatment effect on the P3 measures, the 
results did not provide support for it. Our prior studies in FMR1 premutation carriers demonstrated reduced P2 
Figure 3. P2 amplitudes (μV) to the first 30 standard tones and the last 30 standard tones within the first 
block of each EEG study, showing a reduced amplitude of responses to the later stimuli (i.e., a habituation 
effect) in the memantine-treated FXTAS group (solid green) and a normal control group (blue), but 
increased amplitudes to later stimuli in the other groups. (**p = 0.002).
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amplitude and an elevated |count-hit| discrepancy in a predominately male FXTAS group24, as well as a higher 
than normal |count-hit| discrepancy in older female FMR1 premutation carriers without FXTAS9. The findings of 
the present study indicate that 1-year of chronic treatment with memantine might reverse some of the attentional 
processing deficits in the premutation carriers with FXTAS.
The precise nature of the auditory P2 is not fully understood, but it is generally agreed that the P2 is sensi-
tive to processes beyond sensation and that attention has significant modulatory effects on this component35,36. 
P2 sensory gating has been related to brain mechanisms that filter potentially interfering stimuli in attention 
allocation. Studies using selective attention tasks suggested that the P2 reflects inhibitory control of automatic 
access to distractors37, or allocation of marginal attentional resources needed for non-target stimuli to be iden-
tified and rejected38,39. Enhanced P2 amplitudes after training have been linked to increased distractor inhibi-
tion40,41. Consistent with these prior studies, the memantine-related P2 amplitude increase in the current study 
likely represents improved distractor inhibition and/or similar processes at an earlier stage of stimulus identi-
fication/discrimination. The improved P2-indexed activities subsequently benefited the attentional processing 
of targets, resulting in treatment-related gains in attention/working memory performance as measured by the 
reduced |count-hit| discrepancy, the trend of better sensitivity (d′ ) for target detection, and normalized habit-
uation of P2 amplitude. The improvements in these behavioral and neural measures, as well as the positive cor-
relation between changes in P2 amplitude and |count-hit| discrepancy during the oddball task, indicate that the 
memantine-associated changes obtained in the current study represent beneficial treatment effects for FXTAS. 
Thus, our present findings support the hypothesis that 1-year of memantine treatment has positive effects on 
some fundamental components of executive function/dysfunction42,43, which are thought to comprise the core 
cognitive deficits in FXTAS5.
Unlike most ERP components, P2 amplitude has been found to increase with normal aging, a phenomenon 
interpreted as an inappropriate orienting response to irrelevant stimuli and a deficient capacity to withdraw atten-
tional resources from irrelevant stimuli36,39 (but also see Polich44 for a lack of age effect on P2). The aging-related 
amplitude increase might have cancelled the FXTAS-associated decrease24 and explains that no P2 amplitude 
reduction was found for the carriers on placebo for one year.
The primary generators of the auditory P2 have been localized in auditory cortex including the lateral Heschl’s 
gyrus36. It is also thought that the thalamo-midbrain reticular activating system and insula are important for P2 
generation45,46. Notably, radiological studies in FXTAS have found alterations in several putative P2 generators 
including insula, superior temporal lobe, and reticular activating system structures (e.g., thalamus and cerebral 
peduncle)47,48. Thus, it is plausible that the NMDA antagonist memantine ameliorates neuronal abnormalities in 
one or several of the putative P2 generators that have a high density of NMDA receptors, such as the reticular 
activating system.
The middle and late-latency cortical ERPs in rodents have shorter latencies but very similar morphology 
and at least partially shared functional significance when compared to human auditory ERP components27. The 
finding of a specific effect of memantine on the P2 among several auditory ERP components is in line with a 
number of prior pharmacologic studies primarily in mice, which have implicated glutamate as having a cen-
tral role in modulations of auditory P2. For instance, early postnatal treatment of mice with NMDA antagonist 
phencyclidine (PCP) has been shown to significantly disrupt auditory gating of the P2, but not N1 or P1 ampli-
tude49. Depending on the specific type and dosage of the NMDA drug administered, P2 amplitude can be either 
enhanced or attenuated. Tikhonravov and colleagues25 have found that low-dose memantine increased the P2 
and N2 amplitudes to deviants. The NMDA antagonist ketamine has been shown to reduce the auditory P2 
amplitude50. NMDA receptor subunit NR1 knock-out mice demonstrated reduced NMDA signaling, as well as 
a surprising absence of the auditory P251. Thus, along with the recent report showing effects of memantine on 
cued memory retrieval and the N400 ERP repetition effect19, our studies support the hypothesis that memantine 
might reduce FMR1 premutation-associated abnormalities in glutamatergic signalling and improve cognition in 
patients with FXTAS.
In summary, our ERP and behavioral data suggest that memantine treatment has a beneficial effect primar-
ily on cognitive abilities, rather than on the more obvious and characteristic motor abnormalities in FXTAS, 
although occasional improvements have been noticed on motor symptoms with memantine treatment of some 
patients with FXTAS. For example, one case study reported that memantine ameliorated FXTAS symptoms 
including tremor, ataxia, neuropathy, depression, and anxiety when combined with venlafaxine in a 65-year old 
female52. Our ERP results demonstrate evidence of target engagement for cognitive function, and may warrant 
further investigations into the effects of memantine in larger FXTAS samples. It would also be of interest to test 
whether the improvement in P2 amplitude associated with memantine treatment persists after washing-out the 
drug, a finding which would support a neuroprotective effect.
One should note that our findings of subtle beneficial effects on cognition may not be strong enough to justify 
the clinical use of memantine in patients with FXTAS, especially without independent replication. A limitation 
of this ERP substudy is that we analysed ERP data from study completers with technically adequate data at both 
timepoints. A potential selection bias is thus introduced, favoring patients who may have had more benign clin-
ical courses. However, it should be noted that the proportion of patients with adequate longitudinal ERP data 
was identical in both treatment arms and most of the reasons for not completing had very similar prevalences 
in both groups. Thus, like Seritan et al.18, we detected no systematic difference in drop-out rates between groups 
and note that memantine was well tolerated. It also remains uncertain whether chronic memantine treatment 
at earlier stages of FXTAS might affect disease onset or progression, or whether extended treatment will show 
continued improvement of cognitive function, or eventually, quality of life. However, considering the lack of any 
proven therapy to date, the cognitive effects of memantine in FXTAS, as revealed by our ERP measures, provide 
important and therapeutically relevant information that could further the development of specific cognitive or 
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disease-modifying therapies for patients with FXTAS and the premutation carriers affected by other disorders 
such as fragile X-associated primary ovarian insufficiency.
In addition to its effects on NMDA receptors, memantine also binds to dopamine D2 receptors53. Since 
atypical motor parkinsonism is very common in FXTAS2,54, it is plausible that some of the cognitive effects we 
observed could be attributed to memantine’s dopaminergic agonist properties. For example, a MEG study55 has 
demonstrated that dopamine antagonists interfere with involuntary attention shifting, and both prolong and 
diminish the P3a, a positive component whose latency window is close to the P2. Studies of memantine in several 
neuropsychiatric disorders other than dementia have found positive and promising results (e.g., overall improve-
ments in ADHD in a preliminary open-label study and mood-stabilizing effects in bipolar disorder patients not 
responsive to standard treatments)56,57. Therefore, the effects of memantine on psychiatric symptoms in FXTAS 
should be examined more closely. Furthermore, clinical trials testing additive or synergistic effects using meman-
tine in combination with other therapeutic agents is another area which may be worthy of further exploration.
Patients and Methods
Participants. Participants included patients with FXTAS enrolled in a comprehensive research study at the 
M.I.N.D. Institute, University of California Davis, between 2007 and 201218. The study was carried out in accord-
ance with the approved guidelines/protocols. All the protocols were approved by the University of California 
Davis Institutional Review Board. Informed written consent was obtained from all subjects prior to their partici-
pation. All the evaluations were performed at the M.I.N.D Institute in Sacramento, California, except for the ERP 
experiments conducted at the Center for Mind and Brain in Davis, California. Further details about the primary 
clinical trial can be seen in the published report18.
From the 88 patients who started the allocated intervention (43 on memantine, 45 on placebo)18, 76 (38 in 
each arm) participated in the ERP substudy. Eleven (11) participants performed the baseline ERP experiment but 
discontinued the intervention trial because of illness or similar reasons (5 on memantine, 6 on placebo; detailed 
reasons reported in Seritan et al.18) and therefore did not have longitudinal ERP data. There were 9 additional 
subjects who did not complete the follow-up ERP studies (5 on memantine, 4 on placebo) because of transpor-
tation issues or inability to schedule an ERP session when the lab was available (participants were from all over 
the United States and each went through intensive testing and travel generally over a 3-day visit). Therefore, 56 
patients (28 in each arm) completed the auditory oddball ERP experiment at both visits (i.e., at the baseline visit 
right before the intervention, and at the follow-up after staying in the trial for one year). In the memantine group, 
4 participants were excluded from further analyses because of either unusable EEG data with excessive artifacts 
(described below, n = 3) or extended gap between two visits (n = 1; interval = 715 days, compared to the group 
mean of 356 days). In the placebo group, 4 patients were excluded due to unusable EEG data with excessive arti-
facts (n = 3) or having a deep-brain stimulator implanted (n = 1). Thus, data from 24 patients from each group 
were analyzed in the present study (Table 1).
Intervention. Tablets identical in appearance containing either 5 mg of memantine or placebo were provided 
by Forest Pharmaceuticals. Titration started with 5 mg/day by mouth for one week, and dosage was increased by 
5 mg each week, until the full maintenance dose of 10 mg twice daily (i.e., 20 mg/day) was achieved by day 22. 
Participants were instructed to keep all other medications unchanged for the duration of the study.
EEG/ERP data collection. EEG during a two-stimulus auditory oddball experiment was recorded in a 
sound-attenuated, dimly-lit chamber. Lower (113 Hz) and higher (200 Hz) frequency pure tones were presented 
at 40 dB above individual hearing level in 4 blocks, each containing 100 tones, with a stimulus onset asynchrony 
jittered from 1.0–1.5 seconds. Prior to each block, subjects were instructed to respond to the infrequent (proba-
bility = 25%) “oddball” tones (high or low target tones, counterbalanced across blocks). A dual task was employed 
in which subjects were instructed to press a button to each target tone, and to also keep a mental count of the 
number of targets in each block. The mental count of target tones was reported immediately following completion 
after each block. 32-channel EEG was recorded with a Nicolet-SM-2000 amplifier (band-pass = 0.016–100 Hz, 
sampled at 250 Hz). (See Olichney et al.58 for more details of the EEG montage used).
Data Analysis. The |count-hit| discrepancy in each block (i.e., the absolute value of the difference between 
correct button-presses and mental count to target tones within a block) was calculated for each participant, as an 
inverse measure (i.e., a lower value represents better performance) of attention/working memory performance 
during the oddball task9,24.
Event-locked EEG segments contaminated with blinks, eye movements, excessive muscle activity, or amplifier 
blocking were rejected using a semi-automated computer algorithm. Artifact-free EEG segments of 1024 ms (with 
a 100 ms pre-stimulus baseline period, and 924 ms post-stimulus onset) were averaged by experimental condition 
to obtain the ERPs.
Based on our prior findings using the same paradigm9,24, mean amplitude and local peak latency of 4 ERP 
components were quantified in the following time windows: N100 (N1, 70–150 ms), P2 (160–260 ms), N200 (N2, 
170–300 ms), and P3 (300–650 ms). The waveforms to both target and standard tones were used to measure N1. 
The P2 was measured from ERPs to standard tones. The N2 component was defined from the difference wave 
(ERPs to targets minus standards). The P3 was measured from both the difference wave and the ERP waveform 
to targets.
ERP measures were submitted to repeated-measures ANOVAs (SPSS 22, IBM) with the between-subjects 
factor of treatment, and the within-subjects factors of visit and electrode. Analyses of N1 and P2 included 4 
fronto-central electrodes (Fz, Cz, FC1/2). Five central channels (Cz, FC1/2, CP1/2) were used for the N2 analyses. 
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P3 analyses were carried out with 26 scalp electrodes (all except FP1/2). The Greenhouse-Geiser correction was 
used to adjust for violations of sphericity, where appropriate.
To further characterize the modulatory effects of memantine on the P2 component, a habituation analysis was 
conducted for P2 amplitude. P2 mean amplitude in response to the first 30 standard tones was compared to the 
amplitude of response to the last 30 standard tones within the first block of each study, with the between-subjects 
factor of treatment, and the within-subjects factors of visit, trial position, and electrode. Data from a group of 16 
age-matched normal controls (mean age = 59.7 years, each of whom only underwent one ERP recording) was 
used to demonstrate the normal habituation effect.
Linear regression was used to examine the correlations between changes (1-year follow-up minus baseline) in 
the |count-hit| discrepancy and in ERP measures for which significant treatment effects were shown. Correlations 
between local peak amplitudes of P2 (measured after application of a 30 Hz low-pass filter) and CGG repeats were 
also tested.
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